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Abstract: The endocannabinoid (EC) system is implicated in many chronic liver diseases, 
including hepatitis C viral (HCV) infection. Cannabis consumption is associated with 
fibrosis progression in patients with chronic hepatitis C (CHC), however, the role of ECs  
in the development of CHC has never been explored. To study this question, anandamide 
(AEA) and 2-arachidonoyl glycerol (2-AG) were quantified in samples of HCV patients and 
healthy controls by gas and liquid chromatography mass spectrometry. Fatty acid amide 
hydrolase (FAAH) and monoaclyglycerol lipase (MAGL) activity was assessed by [3H]AEA 
and [3H]2-AG hydrolysis, respectively. Gene expression and cytokine release were assayed 
by TaqMan PCR and ELISpot, respectively. AEA and 2-AG levels were increased in plasma 
of HCV patients, but not in liver tissues. Hepatic FAAH and MAGL activity was not 
changed. In peripheral blood mononuclear cells (PBMC), ECs inhibited IFN-γ, TNF-α, and 
IL-2 secretion. Inhibition of IL-2 by endogenous AEA was stronger in PBMC from HCV 
patients. In hepatocytes, 2-AG induced the expression of IL-6, -17A, -32 and COX-2, and 
enhanced activation of hepatic stellate cells (HSC) co-cultivated with PBMC from subjects 
with CHC. In conclusion, ECs are increased in plasma of patients with CHC and might reveal 
immunosuppressive and profibrogenic effects. 
Keywords: endocannabinoid system; hepatitis C; peripheral blood mononuclear cells; 
inflammation; fibrosis; liver 
 
1. Introduction 
The endocannabinoid system comprises endocannabinoids (ECs), with arachidonoyl ethanolamide 
(anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) as prominent examples, cannabinoid receptors 
CB1 and CB2, and EC degradation enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol 
lipase (MAGL). AEA and 2-AG are derivatives of arachidonic acid (AA) conjugated with either 
ethanolamine or glycerol, respectively, and are synthesized on demand from phospholipid precursors 
residing in the cell membrane in response to a rise of intracellular calcium levels. Inside the cells, AEA 
is hydrolyzed by FAAH into AA and ethanolamine while 2-AG is hydrolyzed by MAGL into AA and 
glycerol [1]. The EC system is involved in many physiological and pathophysiological processes, mainly 
of the CNS, but it also exerts numerous regulatory effects on inflammation, metabolism and vascular 
tone. Regarding liver diseases, CB1 and CB2 seem to play opposite roles, with CB2 exerting protective 
effects against the evolution of steatosis, inflammation, and fibrosis [2–4], and CB1 promoting these 
events instead [5]. EC formation is faint in patients without liver disease, whereas in cirrhosis, fatty liver, 
acute hepatitis or bile duct obstruction, hepatic and plasma levels of AEA and 2-AG are reported to be 
increased, with AEA being mainly produced by Kupffer cells and lymphocytes and 2-AG derived from 
hepatic stellate cells (HSC) and hepatocytes [6–11]. Multiple effects of ECs were described, including 
potent anti-inflammatory activity, apoptosis induction, inhibition of cell proliferation, suppression of 
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cytokine production, and induction of T-regulatory cells (Tregs) [1,12–16]. Accordingly, significant 
suppression of IL-2 production by 2-AG was observed in leukocytes via activation of PPAR-γ [17], 
whereas the stimulation of CB2 in Kupffer cells prevented the switch to a pro-inflammatory M1 
phenotype and enhanced transition towards the anti-inflammatory M2 phenotype [18].  
Hepatitis C virus (HCV) infection is among the most frequent causes of chronic liver injury leading 
to cirrhosis. Recent experimental and clinical data in humans demonstrate an association of ECs  
and cannabinoid receptors with liver disease progression, including chronic hepatitis C (CHC) and  
non-alcoholic fatty liver disease (NAFLD) [19,20]. Patients with CHC and daily cannabis consumption 
showed more severe fibrosis than non- or occasional consumers [21–23]. In vitro, HCV-transfected 
hepatocytes showed a strong upregulation of CB1 [24]. However, the particular role and effects of ECs 
in viral-induced liver damage is still incompletely defined. Therefore, we aim to explore the levels of 
ECs in healthy and diseased cohort of HCV patients and to evaluate whether and how possible alterations 
could affect immune and fibrogenic responses. 
2. Results 
2.1. Endocannabinoid (EC) Levels Are Increased in Plasma of Patients with Chronic Hepatitis C (CHC) 
The levels of ECs AEA and 2-AG were approximately twofold higher in plasma of patients with HCV 
compared to healthy controls (p < 0.005) (Figure 1A), whereas in the liver 2-AG was not changed 
significantly (Figure 1B) and AEA was below detection limits (not shown). A panel of other related 
primary fatty acid amides was measured in parallel (linoleoylethanolamide (LEA), palmitoylethanolamide 
(PEA), oleoylethanolamide (OEA), arachidonic acid (AA)) and, again, no significant differences 
between HCV and controls groups were observed, except of a stress response marker cortisol, which 
was induced twofold in the HCV group (Figure 1B).  
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Figure 1. Endocannabinoid (ECs) and related fatty acid amides expression in hepatitis C. 
(A) Levels of ECs in plasma from patients with chronic hepatitis C (CHC) (n = 57)  
and healthy controls (n = 25); (B) levels of ECs, fatty acids amides and cortisol in control  
(n = 9) and hepatitis C virus (HCV)-infected (n = 17) liver tissues. * p = 0.0389 vs. control. 
Interestingly, there was no significant correlation found between plasma EC levels and liver 
inflammation or fibrosis stages in HCV patients (Table 1). 
Table 1. Predictors of high endocannabinoids among hepatitis C virus (HCV) patients. 
Anandamide 
Parameter Unadjusted Coefficients 95% CI p-Value 
Adjusted 
Coefficients 95% CI p-Value 
Age −0.00066 −0.009–0.007 0.87 −0.0036 0.013–0.0057 0.45 
Female 0.075 −0.08–0.23 0.35 0.14 −0.04–0.33 0.13 
BMI 0.011 −0.009–0.032 0.27 0.018 −0.0045–0.041 0.12 
Diabetes 0.16  −0.12–0.43 0.26 0.14 −0.16–0.45 0.35 
Alcohol 0.046 −0.18–0.27 0.69 0.056 −0.21–0.32 0.68 
ALT 0.0006 −0.0003–0.002 0.20 0.001 −0.0005–0.0026 0.18 
AST 0.00064 −0.0007–0.002 0.35 −0.0003 −0.0025–0.0019 0.81 
Fibrosis grade 
(0–2 vs. 3/4) −0.30 −0.20–0.24 0.73 −0.09 −0.28–0.10 0.36 
Fibrosis grade 
cont. −0.0034 −0.063–0.056 0.91    
Genotype  
(1 vs. 2–4) 0.087 −0.071–0.25 0.28    
Activity grade  
(1 vs. 2, 1 vs. 3) 
0.082  
−0.27 
−0.16–0.33  
−0.98–0.43 
0.51  
0.45    
Steatosis −0.092 −0.33–0.14 0.44    
2-AG 0.012 −0.069–0.092 0.78    
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Table 1. Cont. 
2-AG 
Parameter Unadjusted Coefficients 95% CI p-Value 
Adjusted 
Coefficients 95% CI p-Value 
Age 0.033 0.009–0.058 0.007 0.043 0.014–0.072 0.004 
Female −0.069 −0.59–0.45 0.80 −0.14 −0.72–0.44 0.64 
BMI 0.018 −0.049–0.085 0.59 0.029 −0.042–0.10 0.42 
Diabetes  −0.15 −1.05–0.75 0.75 −0.54 −1.49–0.41 0.27 
Alcohol  −0.33 −1.06–0.40 0.38 −0.07 −0.91–0.77 0.87 
ALT 0.003 −0.002–0.007 0.23 −0.00008 −0.005–0.005 0.97 
AST 0.002 −0.0009–0.005 0.17 0.0027 −0.004–0.01 0.44 
Fibrosis grade 
(0–2 vs. 3/4) −0.03 −0.58–0.51 0.90 −0.25 −0.85–0.35 0.41 
Fibrosis grade 
cont. 0.009 −0.18–0.20 0.93    
Genotype  
(1 vs. 2–4) 0.087 −0.071–0.25 0.28    
Activity grade  
(1 vs. 2, 1 vs. 3) 
0.15  
−0.43 
−0.56–0.86  
−2.50–1.63 
0.69  
0.68    
Steatosis −0.52 −1.21–0.18 0.14    
Adjustment performed for: age, gender, BMI, diabetes, alcohol, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and fibrosis grade. 
2.2. Activities of EC Degradation Enzymes Are not Affected in CHC Patients 
The expression of corresponding EC degradation enzymes was measured in parallel in peripheral 
blood mononuclear cells and liver tissues from healthy controls and HCV patients. Surprisingly, FAAH 
and MAGL mRNA was not changed significantly in PBMC from HCV-infected patients, but strongly 
downregulated in liver tissues compared to controls (p < 0.05) (Figure 2A,B). In spite of significant 
mRNA changes, the enzyme activities of FAAH and MAGL in the liver were not altered significantly 
in the CHC group (Figure 2C). 
2.3. 2-AG Has a Major Impact on Expression of Components of the EC System in PBMC 
The basal gene expression levels for FAAH, MAGL, CB1, and CB2 were measured in peripheral 
blood mononuclear cells (PBMC) from healthy controls to evaluate the possible mechanisms and 
regulation. The expression of MAGL was more than 100-fold higher when compared to FAAH mRNA, 
and CB2 mRNA was 10-fold higher than that for CB1 (Figure 3). Upon treatment with ECs, 20 µM  
2-AG caused significant expression of CB1, as well as both degradation enzymes FAAH and MAGL 
after 24 h of incubation in culture, whereas 2.5 µM AEA was not effective (Figure 3). 
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Figure 2. Fatty acid amide hydrolase (FAAH) and monoaclyglycerol lipase (MAGL) mRNA 
and activity in CHC patients and healthy controls. (A) FAAH mRNA and MAGL mRNA in 
liver biopsies from CHC patients and control livers; (B) FAAH mRNA and MAGL mRNA 
in PBMC from CHC patients and healthy controls; (C) FAAH and MAGL enzymatic activity 
in liver biopsies from CHC patients and control livers. ns—not significant. 
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Figure 3. Internal regulation of the EC system by arachidonoyl ethanolamide (AEA) and  
2-arachidonoyl glycerol (2-AG). Cannabinoid receptors CB1, CB2, FAAH and MAGL 
mRNA expression in peripheral blood mononuclear cells (PBMC) by AEA (2.5 µM) and  
2-AG (20 µM) was measured by TaqMan PCR and normalized to 18S RNA. * p < 0.05 vs. 
untreated control. 
2.4. ECs Suppress Inflammatory Cytokine Production in PBMC 
Treatment with AEA and 2-AG led to a downregulation of IFN-γ, TNF-α, I2, and IL-10 mRNA in 
PBMC from subjects with CHC but not from healthy controls (Figure 4A). At the protein level, ECs 
significantly reduced the release of all cytokines in both groups, except for IL-10 by 2-AG (Figure 4B). 
Furthermore, specific inhibition of the AEA degrading enzyme FAAH by PF-622 at 1 µM resulted in a 
decrease of IL-2 production in both healthy subjects and in HCV patients, and this suppression was much 
stronger in the latter (Figure 4C). These effects were cell death-independent, as confirmed by FACS 
analysis (Figure S1). 
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C 
Figure 4. Inflammatory cytokines expression after EC treatment in PBMC. IFN-γ, TNF-α, 
IL-2 and IL-10 mRNA (A) and protein secretion (B) in phytohaemagglutinin (PHA)-stimulated 
PBMC isolated from healthy controls and HCV patients (n ≥ 10 each group); (C) IL-2 
production after FAAH inhibition with PF-622 (1 µM). Results are expressed as arbitrary 
units or spot-forming cells (SFC) per 1 × 106 cells. * p < 0.05; ** p < 0.005; *** p < 0.0005 
vs. corresponding controls. 
2.5. ECs Reduce Inflammatory Response from HCV-Activated PBMC 
Different peptide pools covering the major part of the HCV genome were applied to PBMC isolated 
from HCV patients. Sufficient induction of IFN-γ was obtained from e1, e2, NS3-1 and NS3-2 pools, 
which was significantly reduced by AEA at 2.5 µM from 20 to more than 50% in some cases (Figure 5A). 
Furthermore, NS3 peptides significantly upregulated CB1 mRNA in PBMC, whereas CB2, FAAH and 
MAGL remained unchanged (Figure 5B). 
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Figure 5. AEA suppresses HCV-induced IFN-γ release in PBMC. (A) IFN-γ production in 
PBMC (n = 6) by HCV peptide pools (5 µg/mL) and 2.5 µM AEA. Results are expressed as 
spot-forming cells (SFC) per 1 × 106 cells; (B) FAAH, MAGL, CB1 and CB2 mRNA in 
PBMC by the NS3 HCV pool. * p < 0.05 vs. corresponding non-treated control. 
2.6. 2-AG Induces Inflammatory Cytokine Expression in Primary Hepatocytes and Fibrogenic 
Activation of HSC 
In hHep, 2-AG induced the expression of IL-6, IL-10, IL-17A, IL-32, and COX-2 mRNA, whereas 
no significant changes occurred after AEA treatment (Figure 6A). TNFα and TGFβ1 mRNA were not 
changed by the EC treatment and IFN-γ and IL-2 mRNA were not detectable in primary hHep (not 
shown). Notably, here the expression of CB1 mRNA was much higher than of CB2, opposing to that of 
the CB receptors’ expression in PBMC (Figure 6B). Stimulation with 2-AG led to further upregulation 
of CB2 mRNA by fivefold (p < 0.05) but not of CB1 mRNA (Figure 6B). 
Co-cultivation of primary hHSC with PHA-stimulated PBMC revealed a strong induction of PCα1(I), 
TGFβR1 and TIMP-1 mRNA in hHSC (Figure 6C). 2-AG further upregulated PCα1(I), αSMA, TGFβR1, 
and TIMP-1 mRNA, whereas TGFβ1 and MMP-1 remained non-significantly changed (Figure 6C). 
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Figure 6. ECs affect inflammatory and fibrogenic hepatic cells activities. (A) Inflammatory 
cytokines mRNA and (B) CB1 and CB2 mRNA in human hepatocytes by 2.5 µM AEA and 
20 µM 2-AG; (C) Fibrosis-related mRNA in hHSC and hHSC co-cultivated with PBMC 
from CHC patients by 2.5 µM AEA and 20 µM 2-AG. * p < 0.05 vs corresponding  
non-treated control. 
3. Discussion 
The involvement of CB1 and CB2 in modulating liver fibrosis, steatosis and cell regeneration has been 
repeatedly demonstrated [3,25,26]; however, the particular role of AEA and 2-AG, as well as EC degrading 
enzymes FAAH and MAGL in the development of CHC is not well known. Few studies showed that 
regular cannabis consumption may promote liver fibrosis and steatosis in CHC patients [21–23], but the 
involvement of EC system in HCV-induced injury has not been well described. 
In the present study we show that AEA and 2-AG are increased in plasma from CHC patients compared 
to healthy controls. In the liver, AEA levels were below detection limits, whereas 2-AG were not different 
between groups. Clugston et al. [27] reported a concomitant reduction of hepatic FAAH expression 
paralleled by an increase of AEA but not of 2-AG in livers of alcohol-fed mice. Therefore, we hypothesized 
that in our study the increase of EC levels might be explained by reduced EC degradation enzymes 
activity. But in spite of a strong downregulation of FAAH and MAGL mRNA expression in the liver, 
the activity of corresponding enzymes was not changed. Comparable FAAH and MAGL activities 
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between groups may be explained by the large interindividual variability, preventing significance due to 
the relatively low numbers of patients. Thus, an increase of ECs in plasma could be explained by enhanced 
EC synthesis in the liver or immune cells or reduced FAAH and MAGL activities from immune cells 
due to the stress from inflammation or tissue injury, as previously suggested by others [3,28–30]. 
As reported previously, the EC system can modulate inflammatory and immune responses [1,3,15,16,29]; 
however, its effects on HCV-specific immune reactions has not been delineated. Here we show that ECs 
suppress inflammatory cytokine secretion in PBMC from non-infected and HCV-infected patients. 
Accordingly, a rise of the endogenously produced AEA in PBMC induced by selective FAAH inhibition 
reduced the release of IL-2 to a much higher extent in HCV samples, thus potentially compromising the 
immune response. 
To elucidate whether HCV directly affects the EC system, we applied various HCV peptides to 
PBMC and found that it markedly induced CB1 mRNA expression. It has been demonstrated that HCV 
stimulates CB1 and 2-AG production in hepatocytes, resulting in a changed expression profile of glucose 
metabolism-related genes and increased steatosis [24,31] and, most interestingly, CB1 antagonists 
inhibit hepatitis C virus production [32] but whether the increase of CB1 impairs PBMC functions still 
remains to be investigated. 
Next, we explored the effects of ECs on inflammation- and fibrosis-related genes in hepatocytes and 
hHSC, in an attempt to extend our previous work showing 2-AG as an inducer of CB1 and αSMA in 
hHSC [33]. Although we were not able to detect a significant difference in 2-AG expression in the livers 
of HCV-infected patients here, it may still be possible that ECs contribute to ongoing liver damage via 
activated and sensitized liver cells. Thus, in primary hepatocytes, and opposite to that in PBMC, 2-AG 
strongly upregulated the expression of IL-6, -10, -17A, -32, and, especially, of COX-2 mRNA, the 
converting enzyme for the main precursor of ECs, arachidonic acid. This observation suggests 
differential and site-specific regulation of EC system, with higher CB1 expression on hepatocytes, 
rendering them more susceptible to the pro-inflammatory effects of ECs, and higher CB2 expression on 
PBMC, making them amenable to the immunosuppressive effects from ECs. Even though CB2 was 
likewise induced to some extent by 2-AG in hepatocytes, this effect did not seem to be sufficient to 
overcome the CB1-mediated induction of inflammatory genes. However, this will unlikely lead to 
increased hepatic inflammation in general, as hepatocytes are not the major contributors to the immune 
response, and ECs-induced immunomodulatory effects are mostly mediated via CB2 on locally residing 
Kupffer cells or hepatic or peripheral T-lymphocytes [12,18,34]. This highlights a careful interpretation 
of the results from in vitro studies performed in single cell types before translating obtained findings to 
the situation in humans. 
To explore this further, we studied the impact of ECs on hepatic fibrogenesis by performing  
a co-cultivation experiment of hHSC with PBMC from HCV-infected subjects. Co-cultivation of PBMC 
with hHSC per se induced a pro-fibrogenic phenotype of hHSC via upregulation of key fibrosis genes 
PCα1(I), TGFβR1 and TIMP-1 mRNA, and 2-AG further enhanced this effect strongly. Nattermann and 
colleagues convincingly demonstrated that the ineffective immune response during HCV infection may 
be directly linked to aggravation of hepatic fibrogenesis, as CD4(+) T cells were shown to stimulate 
anti-fibrotic NK cell activity via IL-2 mediated upregulation of NKG2D, and an impaired activity of 
CD4(+) T cells contribute to acceleration of liver fibrosis [35]. 
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Thus, the question of whether increased ECs in CHC promote liver disease progression due to 
impaired systemic immune response and stimulated fibrogenesis, or alleviate these processes via CB2 
activation still remains an open question, as effects are at least in part counteractive [36,37]. 
Immunosuppressive effects of tetrahydrocannabinol and other cannabinoids have been shown in B-,  
T-, NK-cells, and macrophages via CB1 and CB2-dependent and -independent mechanisms [15,16], 
whereas in the liver, direct favorable effects of ECs on inflammation and oxidative stress have been 
shown in ischemia reperfusion experimental models in rodents [38]. 
In conclusion, we found that AEA and 2-AG are increased in patients with CHC, and that HCV may 
directly affect the EC system via regulation of CB receptor expression. Increased EC levels during HCV 
infection might suppress inflammatory cytokines production, thereby weakening the immune response 
towards HCV infection. In addition, ECs may aggravate liver fibrosis via direct HSC activation. Whether 
the EC system halts or perpetuates chronic liver damage, and can thus be a therapeutic target in chronic 
HCV infection, still remains to be elucidated in more details in vivo to account for various confounding 
factors such as disease stage, viral load, immune status, presence of fibrosis or degree of hepatic 
inflammation, steatosis, and probably others, calling for a note of caution in targeting the EC system in 
the treatment of CHC [37]. 
4. Material and Methods 
4.1. Human Tissues and Patients’ Characteristics 
EC levels and EC degradation enzymes activity were measured in liver tissues and plasma samples 
from patients with CHC and from healthy controls. Plasma samples were obtained from HCV patients 
(n = 57) (Inselspital, Bern) and healthy volunteers (n = 25) according to a strict standard operating 
procedure (SOP) (Supporting Information). Snap-frozen liver tissues were obtained from consecutive 
HCV patients (Inselspital Bern, Switzerland) who underwent percutaneous liver biopsies for diagnostic 
reasons (n = 17). All biopsies were evaluated for fibrosis and inflammatory activity according to the 
standard METAVIR scoring system. Histologically normal liver biopsies from patients who underwent 
bariatric surgery (Department of Visceral Surgery, University of Schleswig-Holstein, Kiel, Germany)  
(n = 6) [39] and cholecystectomy (Inselspital, Bern) (n = 3) served as controls. The human study was 
approved by the ethical committees of the two participating centers. All patients and volunteers gave 
written informed consent to have their biological materials assayed in a retrospective study. Patients’ 
characteristics are summarized in Tables 2 and 3. 
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Table 2. Patients’ characteristics (plasma samples). 
 Control HCV 
Number of patients 25 57 
Female (n, %) 15 (60) 22 (38.6) 
Age (mean, SD) 44.2 (11.4) 52.7 (10.0) 
Diabetes (n, %) 0 5 (8.8) 
BMI (mean, SD) NA 24.7 (3.8) 
ALT (mean, SD) NA 115.8 (84.4) 
AST (mean, SD) NA 91.1 (58.8) 
INR (mean, SD) NA NA 
Albumin (mean, SD) NA NA 
CHILD   
A  14 (24.6) 
B  2 (3.5) 
C  0 
Unknown/NA 25 (100.0) 41 (71.9) 
Fibrosis stage   
0  4 (7.0)  
1  21 (36.8) 
2  11 (19.3) 
3  5 (8.8) 
4  15 (26.3) 
Unknown/NA 25 (100.0) 1 (1.8) 
Activity grade   
  19 (33.3) 
  14 (24.6) 
  1 (1.8) 
Unknown/NA 25 (100.0) 23 (40.4) 
Steatosis   
No  15 (26.3) 
Yes  16 (28.1) 
Unknown 25 (100.0) 26 (45.6) 
Genotype   
1  2 (3.5) 
1A  11 (19.3) 
1B  18 (31.6) 
2  8 (14.0) 
3  14 (24.6) 
4  3 (5.3) 
Negative  1 (1.8) 
Unknown/NA 100 (100.0) 0 (0.0) 
Viral load (mean/SD)  
Missing 
NA 
2,182,222 (2,705,243)  
1 (1.8) 
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Table 3. Patients’ characteristics (liver biopsies). 
 Control (Bariatric Surgery) HCV 
Number of patients 6 17 
Female (n, %) 4 (66) 6 (35.3) 
Age (mean, SD) 34 (8.4) 57.5 (12.7) 
Diabetes (n, %) 6 (100) NA 
BMI (mean, SD) 49.5 (7.3) NA 
ALT (mean, SD) NA NA 
AST (mean, SD) NA NA 
INR (mean, SD) NA NA 
Albumin (mean, SD) NA NA 
CHILD   
A  5 (29.4) 
B  0 (0.0) 
C  0 (0.0) 
Unknown/NA   
Fibrosis stage   
0 6 (100.0)  1 (5.9) 
1  0 (0.0) 
2  3 (17.6) 
3  8 (47) 
4  5 (29.4) 
Unknown/NA   
Activity grade   
1  6 (35.3) 
2  10 (58.8) 
3  1 (5.9) 
Unknown/NA   
Steatosis   
No 6 (100.0) 5 (29.4) 
Yes  12 (70.5) 
Unknown   
Genotype 6 (100.0)   
1   
1A  12 (70.5) 
1B  NA 
2  NA 
3  1 (5.9) 
4  2 (11.7) 
Negative Unknown/NA 6 (100.0) 2 (11.7) 
Viral load (mean/SD) NA 2,530,938 (3,483,784) 
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4.2. Materials 
Human peripheral blood mononuclear cells (PBMC) were obtained from whole blood via  
density-gradient centrifugation as previously described [40]. Primary human hepatic stellate cells 
(hHSC) and primary human hepatocytes (hHep) were obtained from ScienCellTM Research Laboratories 
(Carlsbad, CA, USA). AEA and 2-AG were obtained from Sigma-Aldrich, Germany; PF-622, URB-597 
and JZL184 from Cayman Chemical, USA; HCV peptide pools from BEI Resources, Manassas, VA, 
USA. Overlapping peptides derived from the HCV strain H77 (genotype 1a) spanning the complete HCV 
polyprotein (18 amino acids each, overlapping by 11 amino acids) were used at a final concentration of  
5 μg/mL [34]. The composition of the peptide pools is provided in Supporting Information (Table S1). 
4.3. Analysis of ECs in Human Plasma Samples and Liver Biopsies 
Plasma levels of ECs were measured by GC-MS, as will be published in detail elsewhere, while in 
the liver, ECs were measured by LC-MS, as described in Supporting Information (Table S2). 
4.3.1. FAAH and MAGL Activity Assay 
Enzyme activities were measured as described previously [41]. Briefly, 1 µM of URB597, JZL-184 
or vehicle was pre-incubated for 30 min at 37 °C with 490 μL of diluted liver tissue homogenates (1 mg 
total protein/sample) in 10 mM Tris-HCl, 1mM EDTA (pH8.0). A mixture of 100 nM AEA plus 1 nM 
[3H]-AEA or 1 µM 2-AG plus 1nM [3H]-2-AG was added and incubated for 15 min at 37 °C.  
The reaction was stopped by transferring the samples to a new tube containing 1 mL of CHCl3/CH3OH 
mixture (1:1, v/v). The solution was vigorously vortexed and then centrifuged at 4 °C for 10 min at 
10,000 rpm to separate aqueous and organic phase. The amount of [3H]ethanolamine (AEA degradation) 
or [3H]glycerol (2-AG degradation) formed upon enzymatic hydrolysis was quantified by adding 3 mL 
of Ultima Gold scintillation liquid (PerkinElmer Life Sciences, Long Island, NY, USA) to the aqueous 
phases and measuring the radioactivity with the Packard Tri-Carb 2100 TR β-counter. 
4.3.2. In Vitro Experiments 
PBMC, hHSC and hHep were cultured in Roswell Park Memorial Institute medium (RPMI), 
Dulbecco’s modified Eagle's medium (DMEM) or hepatocyte medium (HM; ScienCell, Carlsbad, CA, 
USA), respectively, containing 10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100 U/mL 
streptomycin. Cells were maintained at 37 °C in 5% CO2 humidified atmosphere.  
hHSC and hHep were seeded onto 12-well plates and, after reaching semi-confluent state, starved in 
serum-free medium for next 24 h. Treatment with 2.5 µM AEA and 20 µM 2-AG, 1 µM PF-622,  
5 µg/mL phytohemagglutinin (PHA) or 5 μg/mL HCV peptides pools was performed for 6–24 h  
in complete medium containing 0.1% FBS. 
Co-cultivation of hHSC and PBMC was performed using 0.4 µm polycarbonate membrane 12 mm 
inserts (Corning Incorporated, Lifesciences, Lausen, Switzerland). 
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4.3.3. Quantitative Real-Time PCR 
Total RNA was isolated from snap frozen tissues or cultured cells using the RNeasy kit  
(Qiagen, Basel, Switzerland) and 1 µg transcribed to cDNA as described [42]. Quantitative real-time 
PCR was performed on the ABI 7700 Sequence Detector (Applied Biosystems, Rotkreuz, Switzerland) 
using ready-to-use primers and probes sets (Applied Biosystems, Rotkreuz, Switzerland).  
For normalization, the housekeeping gene 18SRNA was amplified in a parallel reaction. 
4.3.4. ELISpot 
Cytokine production was determined by ELISpot assay (MABTECH, Stockholm, Sweden) according 
to the manufacturer’s instructions as previously described [34,40,43,44]. Briefly, PBMC were seeded at 
1 × 106 cells/mL and pre-incubated in RPMI with or without ECs for 3 h at 37 °C before stimulation 
with PHA or HCV peptides, where applicable. The vehicle alone was used as a negative control. 
4.4. Statistical Analysis 
Statistical analyses were performed using Microsoft Excel and GraphPad Prism software. Data are 
expressed as means ± SD. The statistical significance of differences was evaluated using paired or 
unpaired Student’s t-test or nonparametric ANOVA Kruskal-Wallis test. Predictions were performed 
using multiple regression analysis. 
Supplementary Materials 
Supplementary materials can be found at http://www.mdpi.com/1422-0067/16/04/7057/s1. 
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